Abstract:Alveolar echinococcosis (AE) is a highly lethal helminth infection. Current chemotherapeutic strategies for AE primarily involve the use of benzimidazoles (BZs) such as mebendazole (MDZ) and albendazole (ABZ), which exhibit limited efficacy. In a previous study, the vaccine of recombinant Echinococcus granulosus P29 (r Eg P29) showed significant immunoprotection against E . granulosus in both mice and sheep. In the current study, we utilized hybridoma technology to generate five monoclonal antibodies (mAbs) against P29, among which 4G10F4 mAb exhibited the highest antigen-specific binding capacity. This mAb was selected for further investigation of anti-AE therapy, both in vivo and in vitro. In vitro, 4G10F4 inhibited a noteworthy inhibition of E . multilocularis protoscoleces and primary cells viability through complement-dependent cytotoxicity (CDC) mechanism. In vivo, two experiments were conducted. In the first experiment, mice were intraperitoneally injected with Em protoscoleces, and subsequently treated with 4G10F4 mAb (2.5/5/10 mg/kg) at 12 weeks postinfection once per week for 8 times via tail vein injection. Mice that were treated with 4G10F4 mAb only in dosage of 5mg/kg exhibited a significant lower mean parasite burden (0.89±0.97 g) compared to isotype mAb treated control mice (2.21±1.30 g). In the second experiment, mice were infected through hepatic portal vein and treated with 4G10F4 mAb (5mg/kg) at one week after surgery once per week for 8 times. The numbers of hepatic metacestode lesions of the 4G10F4 treatment group were significantly lower in comparison to the isotype control group. Pathological analysis revealed severe disruption of the inner structure of the metacestode in both experiments, particularly affecting the germinal and laminated layers, resulting in the transformation into infertile vesicles after treatment with 4G10F4. In addition, the safety of 4G10F4 for AE treatment was confirmed through assessment of mouse weight and evaluation of liver and kidney function. This study presents antigen-specific monoclonal antibody immunotherapy as a promising therapeutic approach against E . multilocularis induced AE. Echinococcosis encompasses two significant zoonotic tapeworm diseases, cystic echinococcosis (CE) and alveolar echinococcosis (AE), caused by Echinococcus granulosus and Echinococcus multilocularis , respectively. AE is widely acknowledged as the most fatal helminth infection, with a mortality rate exceeding 90% within 10–15 years of diagnosis if left untreated or inadequately treated. Two benzimidazole carbamates, albendazole and mebendazole, are the only anti-infective drugs that are clinically efficient in interrupting the larval growth of Echinococcus spp. However, due to their toxicity and limited efficacy, there is a pressing need to explore novel therapeutic strategies for AE. In this study, a therapeutic antibody named 4G10F4 was produced against hydatid P29 using hybridoma technology. This candidate antibody significantly inhibited E . multilocularis both in vitro and in vivo, representing a potentially efficacious and safe antigen-specific monoclonal antibody immunotherapy for the treatment of AE. Additionally, it has been identified as a promising antibody drug and molecular target for the development of anti-AE therapy.

Effect of Tetramethylpyrazine Combined with Albendazole on the Secondary Alveolar Echinococcosis in Mice

[Effect of Combined Pentoxifylline and Albendazole Against Echinococcus Multilocularis Infection in Mice].

Effect of Matrine and Albendazole on Echinococcus Multilocularis Infection in Mice

Effects of matrine combined with albendazole on the secondary echinococcosis in mouse

Study on Growth Inhibition of Echinococcus Granulosus in Mice and Its Mechanism of Tetrandrine and Albendazole

Efficacy of Albendazole Chitosan Microsphere Against Echinococcus Multilocularis Infection in Mice

Ubenimex Combined with Albendazole for the Treatment of Echinococcus Multilocularis-Induced Alveolar Echinococcosis in Mice

OBSERVATION ON THE EFFICACY OF ARTESUNATE AGAINST MURINE ECHINOCOCCOSIS

[Efficacy of Albendazole Chitosan Microspheres Against Echinococcus Granulosus Infection in Mice].

Suppressive effect of pseudolaric acid B on Echinococcus multilocularis involving regulation of TGF-β1 signaling in vitro and in vivo

Albendazole in combination with artesunate to prevent the recurrence of cystic echinococcosis in mice

Synergism Therapeutic and Immunoregulatory Effects of Albendazole + Rad-Mil-28b Against Echinococcosis in Experiment-Infected Mice with Protoscoleces

THE STUDY ON TETRANDRINE AGAINST ECHINOCOCCUS MULTILOCULARIS PROTOSCOLECES IN VITRO

Therapeutic Effects of Sophora Moorcroftiana Alkaloids in Combination with Albendazole in Mice Experimentally Infected with Protoscolices of Echinococcus Granulosus

[Effect of the Liposome Albendazole and Huai-Er Fungus Extract on Hepatic Infection of Echinococcus Granulosus in Mice].

Evaluation of Allicin Against Alveolar Echinococcosis in Vitro and in a Mouse Model

In Vitro and in Vivo Efficacies of Carbazole Aminoalcohols in the Treatment of Alveolar Echinococcosis.

Enhancing the therapeutic potential of P29 protein-targeted monoclonal antibodies in the management of alveolar echinococcosis through CDC-mediated mechanisms

Pharmacology and Efficacy of Liposome-Entrapped Albendazole in Experimental Secondary Alveolar Echinococcosis and Effect of Co-Administration with Cimetidine

Effects of Echinococcus Multilocularis Metacestodes Infection and Drug Treatment on the Activities of Biotransformation Enzymes in Mouse Liver

In Vivo Evaluation of the Efficacy of Sophora Moorcroftiana Alkaloids in Combination with Bacillus Calmette–Guérin (BCG) Treatment for Cystic Echinococcosis in Mice